For research use only. Not for therapeutic Use.
Enbezotinib（Cat No.:I045111）is an investigational oral tyrosine kinase inhibitor (TKI) targeting multiple oncogenic drivers, including epidermal growth factor receptor (EGFR) mutations and HER2 alterations. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors with EGFR exon 20 insertions or HER2-driven oncogenesis. Enbezotinib is designed to overcome resistance to first- and second-generation EGFR inhibitors while minimizing off-target effects. Its broad-spectrum activity and favorable pharmacokinetics support its potential as a precision therapy. Supplied for research into EGFR/HER2-targeted oncology and drug resistance mechanisms.
| CAS Number | 2359649-81-1 |
| Synonyms | (3S,7R,17S)-12-fluoro-17-methyl-2,16-dioxa-8,14,19,23,24,26-hexazahexacyclo[22.3.1.03,7.08,27.010,15.021,25]octacosa-1(28),10(15),11,13,21(25),22,26-heptaen-20-one |
| Molecular Formula | C21H21FN6O3 |
| Purity | ≥95% |
| IUPAC Name | (3S,7R,17S)-12-fluoro-17-methyl-2,16-dioxa-8,14,19,23,24,26-hexazahexacyclo[22.3.1.03,7.08,27.010,15.021,25]octacosa-1(28),10(15),11,13,21(25),22,26-heptaen-20-one |
| InChI | InChI=1S/C21H21FN6O3/c1-11-6-23-20(29)14-8-25-28-10-17-19(26-18(14)28)27(15-3-2-4-16(15)31-17)9-12-5-13(22)7-24-21(12)30-11/h5,7-8,10-11,15-16H,2-4,6,9H2,1H3,(H,23,29)/t11-,15+,16-/m0/s1 |
| InChIKey | BYYQDEOVMILBQT-XZJROXQQSA-N |
| SMILES | C[C@H]1CNC(=O)C2=C3N=C4C(=CN3N=C2)O[C@H]5CCC[C@H]5N4CC6=C(O1)N=CC(=C6)F |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
